GAMP 5 Edition 2 & FDA CSA: The Validation Revolution No One's Talking About

Validation in pharma is at a crossroads. GAMP 5 Edition 2 (July 2022) rewrote the rulebook around critical thinking. The FDA's CSA draft guidance (September 2022) said the exact same thing from the regulator's side. The EU Annex 11 revision (July 2025) reinforced it again. Three global documents. One unified direction. Yet most organisations are still validating the way they always have.

The revolution is happening. Most teams are missing it.

What This Webinar Covers:

This 75-minute session cuts through the noise and shows you exactly what has changed, why it matters, and how to apply it without losing your inspection defensibility.

What You Will Learn:

What GAMP 5 Edition 2 Actually Changed — Beyond the marketing speak. The critical thinking concept. The simplified V-model. Why agile is now legitimate in GxP. What the new ML/AI annex actually expects from you.

• How to Apply FDA CSA's Least-Burdensome Principle Without Risk — The CSA says "risk-based, not document-heavy." Sounds good in theory. This session shows you how to apply it while keeping your validation defensible in an audit.

• Where EU Annex 11 Draft Converges with Both — The regulatory convergence is real. Understanding it means you can build validation strategies that work across US, EU, and local markets simultaneously.

• A Real Practitioner Story — One validation programme's before and after. What changed. What stayed the same. What the team learned. No theory. Pure practitioner reality.